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Abstract 
Lenalidomide is a recent thalidomide analog used for the treatment of refractory 
multiple myeloma. The main toxicity of this drug consists in severe neutropenia and 
thrombocytopenia. Lenalidomide-associated liver injury is rare, manifesting itself as 
elevated liver enzymes and hyperbilirubinemia reversible upon weeks after drug 
withdrawal. We report here in detail the clinical course as well as the biological and 
histological alterations of an acute lenalidomide-induced liver injury. Findings on liver 
biopsy allowed us to discriminate acute inflammatory changes due to the drug and 
minor associated lesions of graft-versus-host disease in this patient with recurrent 
myeloma after allogeneic bone marrow transplantation. 
Introduction 
Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic 
syndromes, with pleiotropic activities including induction of apoptosis, inhibition of 
angiogenesis and broad immunomodulatory effects [1]. It has been approved by the 
Food and Drug Administration (FDA) in the United States and by the European 
Medicines Agency (EMEA) in 2007 for the use in combination with dexamethasone in 
the treatment of relapsed or refractory multiple myeloma [2]. This association has been 
well tolerated, more effective than thalidomide plus dexamethasone and less frequently 
associated with peripheral neuropathy in a recent case-control study [3]. The main 
toxicity of lenalidomide consists in myelosuppression with severe neutropenia and 
thrombocytopenia in approximately 60 and 30% of cases, and venous thromboembolism 
in about 10% of 222 patients taking lenalidomide 30 mg daily [1]. Nonhematologic 
grade 3 and 4 toxicity includes fatigue, muscle weakness, skin rash, and elevated liver 
enzymes in 3% of patients under lenalidomide 25 mg daily in association with  
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dexamethasone [4]. Lenalidomide has been associated with marked elevation in liver 
enzymes and hyperbilirubinemia reversible upon weeks after drug withdrawal [5, 6], but a 
detailed description of histological lesions has never been reported so far. We report here 
a detailed clinical, biological and histological observation of acute hepatitis in a patient 
taking lenalidomide.  
Case Report 
A 50-year-old man had a multiple myeloma diagnosed in January 2008 for which he initially 
received radiotherapy, surgery and chemotherapy with bortezomib and dexamethasone. Due to disease 
progression, he was treated in August 2008 with lenalidomide 25 mg daily that was stopped after 
3 months due to a severe skin rash with angioedema that reversed 4 weeks after the drug was stopped. 
During this period, liver function tests remained normal. In November 2008, he received autologous 
stem cell transplantation that induced disease remission until September 2009, when he presented with 
recurrent bone lesions and light chain deposition. Chemotherapy including cyclophosphamide, 
thalidomide and dexamethasone was associated with a decrease in light chain production but did not 
affect bone lesions, which increased in size. Thus stem cell therapy was again considered and an 
allogeneic transplantation was performed on March 2010 after conditioning with melphalan, 
anti-lymphocyte globulin, fludarabine and prednisolone. To prevent graft-versus-host disease (GVH), 
cyclosporine and mycophenolate mofetil were administered. During this period, liver transaminases 
remained below two times the upper limit of normal. Other routine daily medications included 
acetylsalicylic acid 100 mg, penicillin 1 mIU, ursodeoxycholic acid 750 mg, esomeprazole 40 mg, 
valacyclovir 500 mg, as well as trimethoprim 80 mg + sulfamethoxazole 400 mg three times a week. 
On July 19, the patient was again started on lenalidomide 10 mg daily for recurrent myeloma 
lesions in the lumbar spine, without clinical allergic manifestations. He did not complain of fever, 
digestive symptoms or skin lesions and declared no alcohol or illicit drug consumption. Routine 
laboratory tests performed on July 28 showed the following: aspartate aminotransferase (AST) 246 IU/l 
(normal <50), alanine aminotransferase (ALT) 509 IU/l (normal <50), alkaline phosphatase 198 IU/l 
(normal <125), gamma-glutamyl transferase 105 IU/l (normal <40), and normal serum bilirubin level. 
At ultrasonography, the liver appeared slightly hyperechoic with patent portal and hepatic veins. 
Lenalidomide was immediately stopped, but the remaining treatment was continued, and a liver biopsy 
was scheduled for August 5. On admission, the patient had no fever and no skin lesions. The right 
hypochondrium was mildly tender at abdominal palpation, but there was no spleen enlargement. 
Laboratory values were as follows: white blood cells 5.6 × 10
9/l (normal 4.11) with 24% eosinophils, 
platelet count was 167 × 10
9/l, C-reactive protein 2.1 mg/l (normal <10), serum creatinine 114 μmol/l 
(normal 62–106), AST 66 IU/l, ALT 219 IU/l, alkaline phosphatase 157 IU/l, gamma-glutamyl 
transferase 67 IU/l, with normal serum bilirubin, INR and factor V values. Serological tests for 
hepatitis A, B, C, E, cytomegalovirus, HIV 1 and 2, Epstein-Barr and Herpes viruses were negative. The 
liver biopsy showed prominent portal and lobular inflammation with a mixed cellular infiltrate rich in 
polynuclear eosinophils, lobular areas of confluent necrosis, and mild lesions of endothelitis and 
occasional biliary cell dystrophy in some portal tracts. There was no histological evidence of 
veno-occlusive disease at Gomori staining, iron overload, or infiltration by myeloma cells. In situ 
hybridization staining for cytomegalovirus and Epstein-Barr viruses was negative. Considering the 
presence of acute portal and lobular alterations associated with numerous polynuclear eosinophils on 
the one hand and the rare lesions of endothelitis and biliary cell dystrophy on the other, we made a 
diagnosis of acute hepatitis associated with mild degree of hepatic GVH. 
Following withdrawal of lenalidomide, biological alterations returned to normal after one month, 
on August 31. The patient was strongly recommended to avoid lenalidomide re-exposure. Figure 1 
illustrates the clinical and biological course of the acute hepatitis, while histological alterations are 
depicted in figure 2.  
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Discussion 
Reported cases of lenalidomide hepatitis are very rare with regards to the popularity 
of this drug for patients with multiple myeloma. Manifestations of this drug-induced 
hepatitis consist in elevated liver enzymes that may be associated with 
hyperbilirubinemia, and these changes have been reversible within weeks following 
discontinuation of the drug [5, 6]. In our patient, a role for lenalidomide in the 
development of acute hepatitis is supported by the pattern of lesions found on the biopsy 
performed early in the course of the disease. Areas of confluent necrosis in the liver lobule 
together with inflammatory changes containing polynuclear eosinophils are elements that 
raise the suspicion of drug-induced liver injury [7]. Another key factor in establishing the 
cause of liver injury is the temporal relationship between administration of the drug and 
manifestations of symptoms, but other factors such as exclusion of alternative diagnoses 
and normalization of laboratory values after withdrawal are also considered [8]. In our 
patient, we used drug-induced liver injury diagnostic scales to assess the strength of the 
association [9, 10]. The likelihood of a causal association between lenalidomide and the 
acute hepatitis ranged from ‘probable’ [9] to ‘highly probable’ [10]. In our patient, liver 
injury was apparently not dose-dependent, not predictable, and should be considered as 
an idiosyncratic toxic liver disease. It is likely that the skin rash and edema following the 
first exposure to lenalidomide played a role of sensitization to the drug, followed by severe 
liver injury after re-exposure. However, this cannot be considered stricto sensu as a 
positive rechallenge when determining the level of causality [9]. 
Interpretation of abnormal liver function tests is challenging in a patient who has both 
cancer and who has received bone marrow transplantation [11]. In this setting, numerous 
etiologies must be considered, including recurrent neoplasia, iron overload, infections, 
GVH and veno-occlusive disease as well as drug-induced liver injury. Abnormal liver 
function tests related to drug hepatotoxicity have been observed in 24% of patients who 
underwent allogeneic bone marrow transplantation, while the cause was attributed to 
GVH and iron overload in 38% of cases [11]. In the present observation, the liver biopsy 
allowed us to discriminate minor alterations of small bile ducts and rare lesions of 
endothelitis suggesting GVH, from the acute liver injury that was strongly suggestive of 
drug-induced hepatitis. 
Drug-induced hepatitis may show different types of liver damage. In our patient, 
the pattern was predominantly cytolytic associated with an immuno-allergic type of 
inflammation which we attributed with relative confidence to lenalidomide. Although 
severe hepatotoxicity due to chemotherapeutic agents is relatively rare as compared to 
other drugs [8], the possibility of acute drug-induced hepatitis must always be considered, 
and a liver biopsy should be discussed whenever it turns to impact the patient’s 
management. 
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Fig. 1. Graphical illustration of liver function test alterations following lenalidomide exposure. ASAT = 
Aspartate aminotransferase; ALAT = alanine aminotransferase; GGT = gamma-glutamyl transferase; 
AP = alkaline phosphatase. 
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Fig. 2. Histological view (hematoxylin-eosin stain, original magnification ×200) showing focal 
confluent necrosis in the liver lobule (white arrows). Inset: View of a portal tract with marked 
inflammation containing numerous polynuclear eosinophils (Eo), associated with biliary cell 
dystrophy (BD) and mild endothelitis of the portal vein (V) (original magnification ×400). 
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